Scandinavian ChemoTech Full Year 2023 Earnings: Misses Expectations

Scandinavian ChemoTech (STO:CMOTEC B) Full Year 2023 Results

Key Financial Results

• Revenue: kr2.98m (up by kr2.51m from FY 2022).
• Net loss: kr21.1m (loss narrowed by 7.3% from FY 2022).
• kr1.52 loss per share (improved from kr2.28 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Scandinavian ChemoTech Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 30%.

Looking ahead, revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Sweden.

Performance of the Swedish Medical Equipment industry.

The company's shares are down 15% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 6 warning signs with Scandinavian ChemoTech (at least 4 which are a bit unpleasant), and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.